Dengue (Dengue Fever)

An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. DENGUE HEMORRHAGIC FEVER is a more virulent form of dengue.
Also Known As:
Dengue Fever; Classical Dengue; Classical Dengue Fever; Classical Dengue Fevers; Classical Dengues; Dengue Fever, Classical; Dengue Fevers, Classical; Dengue, Classical; Dengues, Classical; Fever, Dengue
Networked: 3639 relevant articles (119 outcomes, 432 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Infection
2. Malaria
3. Thrombocytopenia (Thrombopenia)
4. Japanese Encephalitis
5. Dengue Hemorrhagic Fever


1. Harris, Eva: 32 articles (10/2015 - 08/2004)
2. Vasudevan, Subhash G: 31 articles (09/2015 - 09/2002)
3. Guzmán, María G: 29 articles (08/2015 - 04/2002)
4. Simmons, Cameron P: 28 articles (12/2015 - 05/2007)
5. Rothman, Alan L: 27 articles (09/2015 - 05/2002)
6. Yoksan, Sutee: 27 articles (09/2015 - 01/2002)
7. Farrar, Jeremy: 26 articles (06/2015 - 07/2002)
8. Ooi, Eng Eong: 25 articles (12/2015 - 08/2005)
9. Alvarez, Mayling: 24 articles (10/2014 - 03/2002)
10. Hermida, Lisset: 23 articles (08/2015 - 08/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dengue:
1. VaccinesIBA
2. Immunoglobulin M (IgM)IBA
3. Immunoglobulin G (IgG)IBA
4. AntigensIBA
01/01/2015 - "Significantly, this molecule identified as an inhibitor of dengue type 2 protease was also effective in inhibiting each one of the four serotypes of dengue viruses in infected cells in culture, based on analysis of viral antigen synthesis and infectious virus production. "
01/01/2015 - "Laboratory dengue diagnosis can be performed through virus isolation, genome and antigen detection and serological studies. "
02/01/2014 - "Paper-based ELISA (specific to serotype-2 dengue fever), which builds off of our previous studies and a revised previous ELISA procedure, owns multiple advantages: 1) high sensitivity (about 40 times higher than the current ELISA-based approaches, due to our therapeutic-based monoclonal antibody) and specificity (specific to dengue virus serotype-2 nonstructural protein-1 antigens); 2) tiny amount of sample and reagent used for single tests; 3) short operating duration (i.e., rapid diagnostic device); and, 4) inexpensiveness (appropriate for use in all developing and underdeveloped nations of the world). "
12/01/2013 - "Taken together, the results of this preclinical study well demonstrate the great potential of ChinDENV for further development as a dengue vaccine candidate, and this kind of chimeric flavivirus based on JE vaccine virus represents a powerful tool to deliver foreign antigens. "
01/01/2013 - "Human leukocyte antigen (HLA) alleles have been correlated with susceptibility or resistance to severe dengue; however, few immunogenetic studies have been performed in Latin American (LA) populations. "
5. AntibodiesIBA
6. Neutralizing AntibodiesIBA
7. Chikungunya virus infectionIBA
8. Dengue VaccinesIBA
10/01/2009 - "Accurate disease surveillance and carefully monitored clinical trials will provide essential evidence concerning the efficacy of candidate dengue vaccines, which will hopefully herald a new era in dengue disease prevention."
01/01/2013 - "For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered."
10/01/2010 - "In this review, we consider the issues impacting conduct and design of dengue vaccine trials with reference to the recently published World Health Organization "Guidelines for Conduct of Clinical Trials of Dengue Vaccines in Endemic Areas." We discuss logistic, scientific and ethical challenges concerning evaluation and introduction of dengue vaccines; these range from randomized trials that establish "proof of concept" of vaccine efficacy, to post-"proof of concept" trials, particularly demonstration projects likely to be required for licensure or for the introduction of an already licensed vaccine into public use. "
02/13/2008 - "Using data gathered from a contingent valuation survey, this study estimated the willingness to pay (WTP) for a single dengue fever vaccine and the household demand function for dengue vaccines. "
12/08/2003 - "Research felt to be key to future decision-making regarding dengue vaccine introduction include: disease surveillance studies, in-country vaccine trials or pilot projects, and studies on the economic burden of dengue and the cost-effectiveness of dengue vaccines. "
9. InsecticidesIBA
10. Monoclonal AntibodiesIBA

Therapies and Procedures

1. Platelet Transfusion (Blood Platelet Transfusions)
2. Tourniquets
3. Blood Transfusion (Blood Transfusions)
4. Insecticide-Treated Bednets
5. Fluid Therapy (Oral Rehydration Therapy)